2015 was a crazy year for the Biotech industry, probably the craziest since the birth of the industry 40 years ago. I looked back on this year and here’s my personal top 3 of EU Biotechs which over-performed. I sorted them out in top partnerships, clinical trials and fundraising.
(Of course, this lists is not exhaustive and is not aimed to be so)
Top Partnerships – M&A deals
Galapagos + Gilead – Abbvie
Galapagos is a billion-euro Biotech from Belgium which had a big partnership with Abbvie. The american Biotech decided not to exercise its options, leaving Galapagos no other choice than finding a new partner. And just before the end of year, Galapagos announced it signed a €2Bn deal with Gilead, the extremely successful Californian Biotech. That’s massive!
Top Clinical Trials Results
Cellectis’ Miracle Saving of a 11-month Baby Girl
CAR-T was the big deal of 2015. This technology using the patient’s own T-Cell to fight cancer is seen as a potential cure for Cancer. The leading European Biotech company in the field is Paris-based Cellectis. Last months, it showed the results from its first patient, a 11-months old british baby girl with terminal Leukemia. She had complete remission after injection of the cells. Impressive!
Bonus article: Exclusive interview of Cellectis’s CEO André Choulika
Immunocore’s monster €300M fundraising
300 million euros is a lot of Money. This has been raised by a single Oxford-based Biotech company. This is actually the biggest private fundraising ever in Europe and the second largest in the World. The company has an robust scientific platform which attracted many top-notch investors including Woodford. It’s great news for the future development of the company and for the European Biotech ecosystem.
Bonus article: Exclusive interview of the CBO of Immunocore
Again, this is just my personal lists. What do you think? What would you have added?